Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in Resistant Langerhans Cell Histiocytosis
NCT00048373Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Oct 2001
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etanercept in Langerhans cell histiocytosis (LCH), sponsored by Baylor College of Medicine. Primary endpoint: Response of Langerhans cell histiocytosis. Started Oct 2001; status: completed.
02
Drugs
etanercept
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT00048373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048373.